<DOC>
	<DOC>NCT01161069</DOC>
	<brief_summary>The purpose this study is to evaluate the safety and toleration of PF-03049423 following multiple dose administration as an oral solution to healthy young adult volunteers and healthy elderly volunteers. The study will also evaluate the pharmacokinetics of PF-03049423 after multiple dose administration to healthy young adult volunteers and healthy elderly volunteers. The study will also explore the relationship between blood pressure (supine and standing) and PF-03049423 concentration.</brief_summary>
	<brief_title>A Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03049423 In Healthy Adult Volunteers And Healthy Older Volunteers</brief_title>
	<detailed_description>The purpose of the investigation is to evaluate the safety and tolerability of an investigational new drug, PF-03049423, when dosed for two weeks in both healthy younger and healthy older subjects.</detailed_description>
	<criteria>Healthy persons, male or female. For the healthy young adult cohort, subjects must be 18 to 50 years old, inclusive. For the healthy elderly adult cohort, subjects must be 51 to 99 years old, inclusive. Body Mass Index (BMI) of 18 to 35; and a total body weight &gt;50 kg (110 lbs) Subjects with clinically significant medical conditions. Women of nonchild bearing potential. Subjects with a known medical history of hearing loss/disability or nonarteritic ischemic optic neuropathy. A positive urine drug screen.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>phase 1</keyword>
	<keyword>healthy young adult volunteers</keyword>
	<keyword>healthy elderly adult volunteers</keyword>
</DOC>